Measuring Biomarkers at Every Stage of Tumor Development
The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.
Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.
Click through the alphabet to see available assays
ANG-1
ANGIOGENESIS FACTOR PANEL 1 (ANG-2, FGFB, HB-EGF, HGF, PLGF, VEGF, VEGF-C)
C-MET
CHEMOKINE PANEL (IP-10, ITAC, MCP-1, MIP-3B)
CHEMOKINE PANEL 1 (RAT) (MCP-1, MIP-1Α, MIP-2, MIP-3Α)
CORPLEX™ CYTOKINE PANEL (IFN-γ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12P70, IL-22, TNFα)
CXCL13 (BCA-1)
CYTOKINE 3-PLEX A TNFα, IL-6, IL-10 (C3PA)
CYTOKINE 6-PLEX PANEL 1 (IFN-γ, IL-6, IL-10, IL-12P70, IL-17A, TNFα)
CYTOKINE PANEL 1 (RAT) (IFN-γ, IL-1β, IL-2, IL-6, IL-10, KC, TNFα)
E-SELECTIN
EOTAXIN (CCL-11) ASSAY KIT
ER (EPIREGULIN)
FGFβ
FIBRINOGEN
GM-CSF
HB-EGF
HE4/ WFDC2
ICAM-1 (MOUSE)
IFN-γ
IFN-γ (MOUSE)
IFN-γ (NON-HUMAN PRIMATE)
IFN-γ (RAT)
IL-10 (RAT)
IL-12 P70
IL-17A
IL-1β
IL-1β (MOUSE)
IL-1β (NON-HUMAN PRIMATE)
IL-1β (PORCINE)
IL-1β (RAT)
IL-2 (MOUSE)
IL-2 (PORCINE)
IL-2 (RAT)
IL-22 (MOUSE)
IL-22 (TOTAL)
IL-6 (NON-HUMAN PRIMATE)
IP-10 (MOUSE)
ITAC
KC (MOUSE)
KC (RAT)
MCP-1 (RAT)
MIP-1α (RAT)
MIP-2 (RAT)
MIP-3β
MIP-4 (PARC)
MMP-2
MMP-9 (MOUSE)
OPN (OSTEOPONTIN)
PD-1 (BEAD)
PD-1 (PLANAR)
PDGFAA
PDGFAB
PLATELET-DERIVED GROWTH FACTOR BB
PlGF
RANKL
RANTES/CCL5
SDF-1 (STROMAL CELL-DERIVED FACTOR 1)
TGFα (BEAD)
TGFα (PLANAR)
TGFβ
TIMP-1
TNF-RI
TNFα
TNFα (MOUSE)
TNFβ
VEGF (MOUSE)
VEGF-C
VEGF-D
VEGF-R1
Simoa® In Action:
Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations.
Olsen et al. Simoa assays were developed to measure AKT, ERK, and cyclin d concentrations in colon cancer patients. Researchers demonstrated an association between levels of these signaling proteins and mutational BRAF status.
Enrichment of circulating tumor-derived extracellular vesicles from human plasma
Yoh et al. Researchers developed and validated an enrichment method for tumor-derived extracellular vesicles (EVs) in the blood of lung and breast cancer patients using Simoa, providing new insights into enrichment of specific EV subtypes for liquid biopsy.
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105
Abrogating GPT2 in triple negative breast cancer inhibits tumor growth and promotes autophagy
Lung tissue inflammatory response and pneumonocyte apoptosis of SD rats after a 30 days exposure in methyl mercaptan vapor
see all related publications
Other Therapeutic Areas